KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBITDA Margin (2016 - 2025)

Pfizer (PFE) has disclosed EBITDA Margin for 17 consecutive years, with 23.02% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 23.02% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.88% through Dec 2025, changed N/A year-over-year, with the annual reading at 33.13% for FY2025, 47426.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 23.02% at Pfizer, up from 341.3% in the prior quarter.
  • The five-year high for EBITDA Margin was 47.01% in Q3 2022, with the low at 2483.26% in Q3 2024.
  • Average EBITDA Margin over 5 years is 188.87%, with a median of 32.79% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -246899bps in 2024, then soared 214196bps in 2025.
  • Over 5 years, EBITDA Margin stood at 32.79% in 2021, then soared by 39bps to 45.45% in 2022, then crashed by -954bps to 387.94% in 2023, then plummeted by -540bps to 2483.26% in 2024, then surged by 101bps to 23.02% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 23.02%, 341.3%, and 34.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.